JP6578037B2 - アポトーシス誘導剤の調製のための方法 - Google Patents
アポトーシス誘導剤の調製のための方法Info
- Publication number
- JP6578037B2 JP6578037B2 JP2018077547A JP2018077547A JP6578037B2 JP 6578037 B2 JP6578037 B2 JP 6578037B2 JP 2018077547 A JP2018077547 A JP 2018077547A JP 2018077547 A JP2018077547 A JP 2018077547A JP 6578037 B2 JP6578037 B2 JP 6578037B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- tert
- organic solvent
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 105
- 238000002360 preparation method Methods 0.000 title claims description 51
- 230000006907 apoptotic process Effects 0.000 title description 3
- 239000000411 inducer Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 194
- 239000003960 organic solvent Substances 0.000 claims description 80
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 61
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical class CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 47
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 27
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- -1 alkyl chloroformate Chemical compound 0.000 claims description 21
- 229910052763 palladium Inorganic materials 0.000 claims description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 239000003446 ligand Substances 0.000 claims description 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 11
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical group CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims description 10
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical group CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 claims description 5
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical group COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 claims description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 105
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 96
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 93
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 92
- 239000000203 mixture Substances 0.000 description 77
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 66
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 63
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 50
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 49
- 239000000243 solution Substances 0.000 description 47
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 46
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 44
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 42
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 42
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 37
- 239000000047 product Substances 0.000 description 34
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 30
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 30
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 30
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 26
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 25
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 24
- 239000007787 solid Substances 0.000 description 24
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 22
- 229940125904 compound 1 Drugs 0.000 description 22
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 22
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 22
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 21
- 229940125782 compound 2 Drugs 0.000 description 21
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 20
- 230000003197 catalytic effect Effects 0.000 description 20
- 238000005481 NMR spectroscopy Methods 0.000 description 19
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 235000019439 ethyl acetate Nutrition 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 17
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 13
- 239000002002 slurry Substances 0.000 description 13
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 10
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 10
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 10
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000003208 petroleum Substances 0.000 description 10
- 239000008096 xylene Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 9
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000376 reactant Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- RXXCIBALSKQCAE-UHFFFAOYSA-N 3-methylbutoxymethylbenzene Chemical compound CC(C)CCOCC1=CC=CC=C1 RXXCIBALSKQCAE-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 150000003512 tertiary amines Chemical class 0.000 description 5
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 4
- 239000004201 L-cysteine Substances 0.000 description 4
- 235000013878 L-cysteine Nutrition 0.000 description 4
- 101150003085 Pdcl gene Proteins 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 3
- IPBPLHNLRKRLPJ-UHFFFAOYSA-N oxan-4-ylmethanamine Chemical compound NCC1CCOCC1 IPBPLHNLRKRLPJ-UHFFFAOYSA-N 0.000 description 3
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 3
- 0 *OC(c(c(F)c1)ccc1Br)=O Chemical compound *OC(c(c(F)c1)ccc1Br)=O 0.000 description 2
- SPZGXONNVLTQDE-UHFFFAOYSA-N 4-chloro-3-nitrobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 SPZGXONNVLTQDE-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000012018 catalyst precursor Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- GNWXVOQHLPBSSR-UHFFFAOYSA-N oxolane;toluene Chemical compound C1CCOC1.CC1=CC=CC=C1 GNWXVOQHLPBSSR-UHFFFAOYSA-N 0.000 description 2
- 238000010966 qNMR Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- ZPGZHSAOCVWZMR-UHFFFAOYSA-N tert-butyl 4-bromo-2-fluorobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(Br)C=C1F ZPGZHSAOCVWZMR-UHFFFAOYSA-N 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 2
- IPRZKPSZGFFWEI-MRVPVSSYSA-N (1S)-1-methyl-4-(nitromethyl)cyclohex-3-en-1-ol Chemical compound C[C@]1(CC=C(CC1)C[N+](=O)[O-])O IPRZKPSZGFFWEI-MRVPVSSYSA-N 0.000 description 1
- FGXQQTSLFAVOCN-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-6-one Chemical compound O=C1CCCCC11OCCO1 FGXQQTSLFAVOCN-UHFFFAOYSA-N 0.000 description 1
- KISZDCHFJKYNFW-UHFFFAOYSA-N 1-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazine;dihydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN1CCNCC1 KISZDCHFJKYNFW-UHFFFAOYSA-N 0.000 description 1
- VUQZKLXKFUBWRP-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridin-5-ol Chemical compound OC1=CN=C2NC=CC2=C1 VUQZKLXKFUBWRP-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- OOUSVDAPSBFSBR-UHFFFAOYSA-N 2-(4-chlorophenyl)-4,4-dimethylcyclohexene-1-carbaldehyde Chemical compound C1C(C)(C)CCC(C=O)=C1C1=CC=C(Cl)C=C1 OOUSVDAPSBFSBR-UHFFFAOYSA-N 0.000 description 1
- BQEJGRDTUMVATJ-UHFFFAOYSA-N 2-phenylcyclohex-3-ene-1-carbaldehyde Chemical compound O=CC1CCC=CC1C1=CC=CC=C1 BQEJGRDTUMVATJ-UHFFFAOYSA-N 0.000 description 1
- ZVJQBBYAVPAFLX-UHFFFAOYSA-N 3,3-dimethylcyclohexan-1-one Chemical compound CC1(C)CCCC(=O)C1 ZVJQBBYAVPAFLX-UHFFFAOYSA-N 0.000 description 1
- QEOXRBGGWGLWLW-UHFFFAOYSA-N 3-chloro-1,1-dimethylcyclohexane Chemical compound CC1(C)CCCC(Cl)C1 QEOXRBGGWGLWLW-UHFFFAOYSA-N 0.000 description 1
- HNQRHNYBVWICKB-UHFFFAOYSA-N 3-nitro-4-(oxan-4-ylmethylamino)benzenesulfonamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)N)=CC=C1NCC1CCOCC1 HNQRHNYBVWICKB-UHFFFAOYSA-N 0.000 description 1
- AAEIBLQPASHLSV-UHFFFAOYSA-N 4,4-dimethylcyclohexane-1-carbaldehyde Chemical compound CC1(C)CCC(C=O)CC1 AAEIBLQPASHLSV-UHFFFAOYSA-N 0.000 description 1
- XRMZKCQCINEBEI-UHFFFAOYSA-N 4-bromo-2-fluoro-1-iodobenzene Chemical compound FC1=CC(Br)=CC=C1I XRMZKCQCINEBEI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- SWKOYTNFSYQAKH-UHFFFAOYSA-N CC1(C)CC(c(cc2)ccc2Cl)=C(CN(CC2)CCN2c(cc2)cc(Oc3cnc4[nH]ccc4c3)c2C(NS(c(cc2)cc([N+]([O-])=O)c2N)(=O)=O)=O)CC1 Chemical compound CC1(C)CC(c(cc2)ccc2Cl)=C(CN(CC2)CCN2c(cc2)cc(Oc3cnc4[nH]ccc4c3)c2C(NS(c(cc2)cc([N+]([O-])=O)c2N)(=O)=O)=O)CC1 SWKOYTNFSYQAKH-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- QTUZSJSEZUZNAS-UHFFFAOYSA-N tert-butyl 4-bromo-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(Br)C=C1OC1=CN=C(NC=C2)C2=C1 QTUZSJSEZUZNAS-UHFFFAOYSA-N 0.000 description 1
- 125000004954 trialkylamino group Chemical group 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
- C07C45/455—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation with carboxylic acids or their derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
- C07C47/457—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
- C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Health & Medical Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Compounds Of Unknown Constitution (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
(b’’)式(L)の化合物を1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド塩酸塩(EDAC)、4−ジメチルアミノピリジン(DMAP)、有機溶媒、
ならびに下記式(N)の化合物と組合わせて、式(A1)の化合物でR2が
(c’’)次式(M):
(d)次式(D):
(e)次式(B)の化合物を次式(C)の化合物:
(f)次式(A):
(g)C1〜C12アルキルクロロホルメートまたはジ−(C1〜C12アルキル)ジカーボネートをステップ(f)の生成物と組合わせて、式(C)の化合物を提供することを含む。
(h)次式(E):
(c)次式(M):
(d)次式(D):
(e)次式(B)の化合物を、次式(C):
(f)次式(A):
(g)C1〜C12アルキルクロロホルメートまたはジ−(C1〜C12アルキル)ジカーボネートをステップ(f)の生成物と組合わせて、式(C)の化合物を提供することを含む。
(h)次式(E):
(c’)次式(M):
(1)tert−ブトキシド塩を式(I)の化合物と非プロトン性有機溶媒中で組合わせる;
(2)パラジウム源、式(J)の化合物、および式(D)の化合物を非プロトン性有機溶媒中で組合わせる;および
(3)ステップ(1)の混合物をステップ(2)の混合物に添加する。
(1)水溶液をステップ(j)の混合物に添加して、水性相および有機相を生成し;
(2)有機相をステップ(1)の混合物から分離し;
(3)有機相を濃縮し;
(4)有機溶媒をステップ(3)の混合物に添加して、式(H)の化合物を結晶性固体として生成する
ことを含む。
(b)C1〜C12アルキルクロロホルメートまたはジ−(C1〜C12アルキル)ジカーボネートをステップ(a)の生成物と組合わせて、式(C)の化合物を提供することを含む。
(x′)次式(A):
(x′′)C1〜C12アルキルクロロホルメートまたはジ−(C1〜C12アルキル)ジカーボネートをステップ(x′)の生成物と組合わせて、式(C)の化合物を提供する。
(y)次式(B):
(1)tert−ブトキシド塩を式(I)の化合物と非プロトン性有機溶媒中で組合わせる;
(2)パラジウム源、式(J)の化合物、および式(D)の化合物を非プロトン性有機溶媒中で組合わせる;および
(3)ステップ(1)の混合物をステップ(2)の混合物に添加する。
機械式攪拌機を備えた100mlのジャケット付き反応器に、4−ブロモ−2−フルオロ−1−ヨードベンゼン、「化合物(A)」(5g、1.0eq)とTHF(25ml)を入れた。溶液を−5℃に冷却した。内部温度を0℃より低く維持しながらTHF中2Mのイソプロピルマグネシウムクロリド(10.8ml、1.3eq)をゆっくり加えた。混合物を0℃で1時間撹拌した。THF(10ml)中のジ−tert−ブチルジカーボネート(5.44g、1.5eq)を加えた。1時間後、溶液を10%クエン酸(10ml)でクエンチした後、25%NaCl(10ml)で希釈した。層を分離し、有機層を殆ど乾固するまで濃縮し、THF(3×10ml)でチェイスした。粗製の油をTHF(5ml)で希釈し、ろ過して無機物を除き、濃縮乾固した。この粗製の油(6.1g、力価=67%、力価調整収率=88%)をさらに精製することなく次のステップに用いた。1H NMR(DMSO−d6):δ 1.53(s、9H)、7.50−7.56(m、1H)、7.68(dd、J=10.5、1.9Hz、1H),7.74(t、J=8.2Hz、1H)。
3Lの三つ首モートンフラスコに、1H−ピロロ[2,3−b]ピリジン−5−オール(80.0g、1.00eq.)、tert−ブチル4−ブロモ−2−フルオロベンゾエート(193g、1.15eq.)、および無水DMF(800mL)を入れた。混合物を20℃で15分撹拌した。得られた溶液を約0から5℃に冷却した。DMF(420mL)中ナトリウムtert−ブトキシド(62.0g)の溶液を30分にわたってゆっくり加える一方で内部温度を10℃以下に維持し、DMF(30mL)で濯いだ。反応混合物を10℃で1時間撹拌し(オフホワイトのスラリー)、30分にわたって内部温度をおよそ45℃に調節した。反応混合物を45〜50℃で7時間撹拌し、反応の進行をHPLCでモニターした(IPサンプル:HPLCによる転化率92%)。溶液をおよそ20℃に冷却した。溶液を20℃で一晩撹拌した。
500mLのRBフラスコに、無水DMF(33.4g、0.456mol)とCH2Cl2(80mL)を入れた。溶液を<−5℃に冷却し、POCl3(64.7g、0.422mol)を<20℃で20分かけてゆっくり加え(発熱)、CH2Cl2(6mL)で濯いだ。やや褐色の溶液を30分かけて20℃に調節し、20℃で1時間混合した。溶液を<5℃に冷却した。3,3−ジメチルシクロヘキサノン(41.0g、90%、およそ0.292mol)を加え、CH2Cl2(10mL)(やや発熱)を用いて<20℃で濯いだ。溶液を還流温度に加熱し、一晩(21時間)混合した。
250mLの加圧びんに、2−クロロ−4,4−ジメチルシクロヘキサ−1−エンカルバルデヒド(10.00g)、臭化テトラブチルアンモニウム(18.67g)、およびアセトニトリル(10mL)を入れた。混合物を20℃で5分撹拌した。21.0wt%のK2CO3水溶液(76.0g)を加えた。混合物を室温(rt)で5分以上撹拌した後4−クロロフェニルボロン酸(9.53g)を全て一緒に加えた。混合物を排気し、N2で三回パージした。酢酸パラジウム(66mg、0.5mol%)をN2下で全て一緒に加えた。反応混合物を排気し、N2で三回パージした(オレンジ色の混合物)。びんをN2で再充填し、油浴(浴温およそ35℃)でおよそ35℃に加熱した。混合物を30℃で一晩(15時間)撹拌した。反応混合物をRTに冷却し、反応の完了、通例出発物質<2%(オレンジ色の混合物)を確認するために上部の有機相からIPサンプルを採取した。トルエン(100mL)と5%NaHCO3−2%L−システイン水溶液(100mL)を加えた。混合物を20℃で60分撹拌した。混合物をセライトのパッドに通してろ過して黒色の固体を除き、フラスコとパッドをトルエン(10mL)で濯いだ。上部の有機相を5%NaHCO3水溶液−2%L−システイン(100mL)でもう一回洗浄した。上部の有機相を25%ブライン(100mL)で洗浄した。有機層(105.0g)を分析し(118.8mg/g、分析された生成物12.47g、分析された収率87%)、およそ1/3の体積(およそ35mL)に濃縮した。生成物溶液を単離することなくそのまま次のステップに使用した。しかし、溶媒の除去により分析サンプルを得、褐色の油を得た。1HNMR(CDCl3):δ 1.00(s、6H)、1.49(t、J=6.6Hz、2H)、2.28(t、J=2.1Hz、2H)、2.38(m、2H)、7.13(m、2H)、7.34(m、2H)、9.47(s、1H)。
機械式攪拌機を備えた2Lの三つ首RBフラスコに、トルエン(250mL)中4’−クロロ−5,5−ジメチル−3,4,5,6−テトラヒドロ−[1,1’−ビフェニル]−2−カルバルデヒド(50.0g)の溶液、BOC−ピペラジン(48.2g)および無水THF(250mL)を入れた。黄色の溶液を20℃で5分撹拌した。ナトリウムトリアセトキシボロヒドリド(52.7g)を少しずつ加えた(注意:内部温度は15分でおよそ29.5℃に上昇した。冷却が必要となるかもしれない)。黄色の混合物をおよそ25℃で4時間以上撹拌した。3時間の反応時間の後HPLCで99.5%の出発物質から生成物への転化率が観察された。
機械式攪拌機を備えた2.0Lの三つ首RBフラスコに、Boc還元的アミン化生成物(化合物(H)、72.0g)とIPA(720mL)を入れた。混合物をrtで5分撹拌し、59.3gの濃縮塩酸塩水溶液をスラリーに加えた。反応混合物をおよそ65℃の内部温度に調節した(透明で無色の溶液が得られた)。反応混合物をおよそ65℃で12時間以上掻き混ぜた。
機械式攪拌機を備えた500mLの三つ首RBフラスコに、4−クロロ−3−ニトロベンゼンスルホンアミド、すなわち化合物M(10.0g)、ジイソプロピルエチルアミン(17.5g)、(テトラヒドロ−2H−ピラン−4−イル)メタンアミン(7.0g)およびアセトニトリル(150mL)を入れた。反応混合物を80℃の内部温度に調節し、12時間以上掻き混ぜた。
総論:この化学は空気と湿気に対して感受性であると考えられる。固体乾燥形態の触媒前駆体は特別な予防策を講じることなく空気中で取り扱い貯蔵することができるが、小量の溶媒と接触しただけでも分解し易くなることがある。その結果、微量の酸素またはその他のコンピテント酸化剤(例えば、溶媒過酸化物)でも触媒前駆体と溶媒との混合に先立って除去しなければならないし、反応中酸素の侵入を防ぐように注意しなければならない。また、望ましくない副産物の形成を防止するために乾燥した機器、溶媒、および試薬を使用するように注意しなければならない。この反応に使用するナトリウムt−ブトキシドは吸湿性であり、使用に先立ってまたは使用中適切に取り扱い貯蔵するべきである。
溶液調製:10%KH2PO4(aq):水(56g)中KH2PO4(6g);2:1ヘプタン/2−MeTHF:ヘプタン(16mL)。
反応に先立つ溶液調製:10%酢酸:水(333g)中酢酸(37mL);5%NaHCO3:水(176g)中NaHCO3(9g);5%NaCl:水(176g)中NaCl(9g)。
ステップA:1.49gのシクロヘキサンジオンモノエチレンアセタール(1.0当量)と15mLのトルエンを適切な反応器に入れた。混合物を30分間10℃で混合した。トルエン−THF(75−25)中の1.4Mメチルマグネシウムブロミド溶液(2.32eq)を別の反応器に入れ、15℃で混合した。出発物質溶液をおよそ10から20℃において4時間で(添加速度=0.1mL/分)グリニャール溶液に滴下して加えた。反応の進行をTLCでモニターした。反応が完了したら、反応混合物を25℃の温度で24%塩化アンモニウム溶液(20mL)にゆっくり入れた。反応混合物を混合し静まらせ、有機層を分離し、水性層を酢酸エチル(3×20mL)で抽出した。合わせた有機層を硫酸ナトリウムの床上でろ過し、ろ液を蒸留乾固により濃縮した。1.57g。粗製の固体を単離し(95%収率)、次のステップに進めた。1H NMR(400MHz、クロロホルム−d1) δ ppm 3.88−4.01(m、4H)、1.85−1.96(m、2H)、1.08−1.64(m、7H)。LCMS−(MS 310および292)。TLC(ヘキサン−EtOAc=1−1)によるRf=0.074。
4−クロロ−3−ニトロベンゼンスルホンアミド(6.5g、27.5mmol)と((1R,4R)−4−ヒドロキシ−4−メチルシクロヘキシル)メタナミニウム4−メチルベンゼンスルホネート(11.26g、35.7mmol)を35mLのアセトニトリル中で組合わせ、撹拌した。N,N−ジイソプロピルエチルアミン(8.88g、68.7mmol)を周囲温度でスラリーに加えると吸熱(200から17.5℃)が起こった。10分後、反応混合物を80℃に加熱し、その温度を24時間維持した。反応の完了をHPLCでモニターした。反応完了後、反応混合物を40℃に冷却した。水(32.5mL)を15分かけて加え、30分間保った。追加の74.5mLの水を30分にわたって加えた。第2の部分の水を加えると直ぐに固体の生成物が沈殿した。1時間40℃で撹拌した後、生成混合物を20℃まで放冷し、12時間撹拌し、その後さらに2時間撹拌しながら0℃まで冷却した。生成物をろ過し、真空下で乾燥して8.8gの生成物(収率93%;純度>99pa%)を得た。1H NMR(400MHz、DMSO−d6) δ ppm 8.52(t、J=5.9Hz、1H)、8.45(d、J=2.2Hz、1H)、7.80(dd、J=9.1、2.3Hz、1H)、7.24−7.30(m、3H)、4.23(s、1H)、1.60−1.74(m、3H)、1.52−1.57(m、2H)、1.26−1.40(m、2H)、1.06−1.25(m、5H)。
スルホンアミド 4−((((1R,4R)−4−ヒドロキシ−4−メチルシクロヘキシル)メチル)アミノ)−3−ニトロベンゼンスルホンアミド(8.00g、23.29mmol)、EDAC−HCl(5.80g、30.3mmol)およびDMAP(8.54g、69.9mmol)をDCM(186mL、14vol)中で混合して金色のスラリーとした。酸、2−((1H−ピロロ[2,3−b]ピリジン−5−イル)オキシ)−4−(4−((4’−クロロ−5,5−ジメチル−3,4,5,6−テトラヒドロ−[1,1’−ビフェニル]−2−イル)メチル)ピペラジン−1−イル)安息香酸(13.3g、23.29mmol)およびTEA(6.49mL、46.6mmol)のDCM(80mL、6 vol)中の溶液を添加漏斗により2.5時間かけて加えた後10mLのDCMで濯いだ。12時間混合した後、N1,N1−ジメチルエタン−1,2−ジアミン(5.09mL、46.6mmol)を加え、撹拌を20℃で5時間続けた。反応混合物を10%HOAc(130mL、3×)で洗浄した。有機層を5%NaHCO3(140mL)と5%NaCl(140mL)で洗浄した。有機層をNa2SO4上で乾燥し、7体積のDCM溶液まで濃縮した。メタノール(10vol、140mL)を2時間かけて滴下して加え、溶液を15℃に冷却したところ生成物が沈殿した。生成混合物を5℃に冷却し、2時間混合した。固体をろ過し、窒素で2時間ブロー乾燥して、17.35gの生成物を得た(収率83%;純度>99.5pa%)。1H NMR(400MHz、DMSO−d6) δ ppm 11.57−11.59(bs、1H)、8.48−8.52(m、2H)、7.97(d、J=2.6Hz、1H)、7.73(dd、J=9.2、2.3Hz、1H)、7.43−7.50(m、3H)、7.29−7.31(m、2H)、6.98−7.03(m、3H)、6.65(dd、J=8.9、2.3Hz、1H)、6.35(dd、J=3.4、1.8Hz、1H)、6.16(d、J=2.2Hz、1H)、4.41−4.44(m、1H)、3.71−3.75(m、2H)、2.98−3.51(m、11H)、2.74−2.76(m、3H)、2.02−2.26(m、6H)、1.88−1.92(m、2H)、1.47−1.70(m、5H)、1.24−1.40(m、4H)、1.08(s、5H)、0.89(s、6H)。
Claims (10)
- Rが、メチル、エチル、n−プロピル、イソプロピル、n−ブチル、tert−ブチル、イソ−ブチルおよびneo−ブチルからなる群から選択される、請求項1に記載の方法。
- R1がイソプロピルである、請求項1に記載の方法。
- Rがエチルであり、C1〜C12アルキルクロロホルメートがエチルクロロホルメートである、請求項1に記載の方法。
- Rがtert−ブチルであり、ジ−(C1〜C12アルキル)ジカーボネートがジ−tert−ブチルジカーボネートである、請求項1に記載の方法。
- Rがメチルであり、C1〜C12アルキルクロロホルメートがメチルクロロホルメートである、請求項1に記載の方法。
- 式(D):
(a)式(A):
(b)C1〜C12アルキルクロロホルメートまたはジ−(C1〜C12アルキル)ジカーボネートをステップ(a)の生成物と組合わせて、式(C):
(x)式(B):
の化合物およびtert−ブトキシド塩と有機溶媒中で組合わせて、式(D)の化合物を提供すること
を含む、前記方法。 - パラジウム源がPd2 (dba) 3である、請求項8に記載の方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780621P | 2013-03-13 | 2013-03-13 | |
US61/780,621 | 2013-03-13 | ||
US201461947850P | 2014-03-04 | 2014-03-04 | |
US61/947,850 | 2014-03-04 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016501441A Division JP6357220B2 (ja) | 2013-03-13 | 2014-03-12 | アポトーシス誘導剤の調製のための方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018138571A JP2018138571A (ja) | 2018-09-06 |
JP6578037B2 true JP6578037B2 (ja) | 2019-09-18 |
Family
ID=50439506
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016501441A Active JP6357220B2 (ja) | 2013-03-13 | 2014-03-12 | アポトーシス誘導剤の調製のための方法 |
JP2018077547A Active JP6578037B2 (ja) | 2013-03-13 | 2018-04-13 | アポトーシス誘導剤の調製のための方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016501441A Active JP6357220B2 (ja) | 2013-03-13 | 2014-03-12 | アポトーシス誘導剤の調製のための方法 |
Country Status (31)
Country | Link |
---|---|
EP (5) | EP3569588A1 (ja) |
JP (2) | JP6357220B2 (ja) |
KR (1) | KR102230339B1 (ja) |
CN (3) | CN105164128B (ja) |
AU (2) | AU2014248742B2 (ja) |
BR (3) | BR112015021540B1 (ja) |
CA (3) | CA3183040A1 (ja) |
CL (1) | CL2015002548A1 (ja) |
CR (1) | CR20150495A (ja) |
CY (1) | CY1120576T1 (ja) |
DK (1) | DK2970263T3 (ja) |
ES (1) | ES2683378T3 (ja) |
HK (2) | HK1251231A1 (ja) |
HR (1) | HRP20181273T1 (ja) |
HU (1) | HUE039046T2 (ja) |
IL (2) | IL240779B (ja) |
LT (1) | LT2970263T (ja) |
MX (1) | MX365343B (ja) |
MY (1) | MY192466A (ja) |
PE (2) | PE20151809A1 (ja) |
PH (2) | PH12015501960B1 (ja) |
PL (1) | PL2970263T3 (ja) |
PT (1) | PT2970263T (ja) |
RS (1) | RS57569B1 (ja) |
RU (1) | RU2660424C2 (ja) |
SG (2) | SG11201507360XA (ja) |
SI (1) | SI2970263T1 (ja) |
TW (2) | TWI631121B (ja) |
UA (1) | UA118667C2 (ja) |
UY (3) | UY35394A (ja) |
WO (1) | WO2014165044A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104370905B (zh) * | 2014-10-22 | 2016-06-01 | 南京友杰医药科技有限公司 | Bcl-2抑制剂ABT-199的合成 |
EP3426655A1 (en) | 2016-03-10 | 2019-01-16 | Assia Chemical Industries Ltd. | Solid state forms of venetoclax and processes for preparation of venetoclax |
CN107089981A (zh) * | 2017-04-24 | 2017-08-25 | 杭州科耀医药科技有限公司 | 一种BCL‑2抑制剂Venetoclax的合成方法 |
JP7467332B2 (ja) | 2017-08-23 | 2024-04-15 | グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド | 新生物疾患の治療のためのbcl-2阻害剤としての縮合複素環式誘導体 |
CN108037196B (zh) * | 2017-11-23 | 2020-06-23 | 中山奕安泰医药科技有限公司 | 一种3-硝基-4-[[(四氢-2h-吡喃-4-基)甲基]氨基]苯磺酰胺的检测方法 |
KR20200108302A (ko) | 2018-01-10 | 2020-09-17 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
WO2020003272A1 (en) | 2018-06-29 | 2020-01-02 | Fresenius Kabi Oncology Ltd. | An improved process for the preparation of venetoclax |
CN108997333A (zh) * | 2018-07-04 | 2018-12-14 | 江苏中邦制药有限公司 | 一种b细胞淋巴瘤因子-2抑制剂abt-199的制备方法 |
WO2020023435A1 (en) | 2018-07-24 | 2020-01-30 | Albany Molecular Research, Inc. | Venetoclax basic salts and processes for the purification of venetoclax |
US20210315904A1 (en) | 2018-08-22 | 2021-10-14 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
WO2020049599A1 (en) * | 2018-09-07 | 2020-03-12 | Msn Laboratories Private Limited, R&D Center | Process for the preparation of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1- yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino] phenyl}sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide) |
CN112079795B (zh) * | 2020-09-16 | 2022-12-09 | 广东莱佛士制药技术有限公司 | 一种维奈托克中间体及其类似物的合成方法 |
IT202100025976A1 (it) | 2021-10-06 | 2023-04-06 | Univ Degli Studi Di Perugia | Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1) |
CN114163369A (zh) * | 2021-12-17 | 2022-03-11 | 武汉工程大学 | 一种含硫/氧酯基芳烃化合物的制备方法 |
CN116496239A (zh) * | 2022-12-14 | 2023-07-28 | 南京哈柏医药科技有限公司 | 一种维奈托克关键中间体及原料药的合成方法 |
EP4421075A1 (en) | 2023-02-27 | 2024-08-28 | KRKA, d.d., Novo mesto | Process for the preparation of venetoclax and intermediates used therein |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB585940A (en) | 1944-09-01 | 1947-02-28 | Kodak Ltd | Bicyclic compounds containing the diphenylamine grouping, process of making them and their use in the colouration of textile materials other than cellulose |
US3813443A (en) | 1970-11-18 | 1974-05-28 | Us Agriculture | Boll weevil sex attractant |
SK288138B6 (sk) | 1999-02-10 | 2013-11-04 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors |
CN102127023B (zh) | 2004-12-02 | 2013-02-06 | 第一三共株式会社 | 7-元环化合物及其制备方法和用途 |
CN1827582A (zh) * | 2006-04-18 | 2006-09-06 | 江苏中丹化工集团公司 | 6-[3-(1-金刚烷基)-4-甲氧基苯基]-2-萘甲酸甲酯的制备方法 |
WO2008134693A1 (en) * | 2007-04-30 | 2008-11-06 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
US8232411B2 (en) | 2008-03-20 | 2012-07-31 | Abbott Laboratories | Methods for making central nervous system agents that are TRPV1 antagonists |
US20100160322A1 (en) * | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
CN106045893A (zh) * | 2009-01-19 | 2016-10-26 | Abbvie 公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
CN101990094B (zh) | 2009-08-05 | 2012-11-21 | 炬力集成电路设计有限公司 | 一种码流分析方法和装置 |
CN102030651A (zh) * | 2009-09-28 | 2011-04-27 | 莱阳市盛华科技有限公司 | 2-氟-4-溴联苯基甲酸乙酯的合成方法 |
TWI520960B (zh) * | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
DE102010027213A1 (de) * | 2010-07-15 | 2012-01-19 | Continental Automotive Gmbh | Verfahren und Steuergerät zum Steuern einer Brennkraftmaschine |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
EP2632436B1 (en) | 2010-10-29 | 2018-08-29 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
UA119150C2 (uk) | 2010-11-23 | 2019-05-10 | Еббві Айрленд Анлімітед Компані | СПОСОБИ ЛІКУВАННЯ З ВИКОРИСТАННЯМ СЕЛЕКТИВНИХ ІНГІБІТОРІВ Всl-2 |
CN107266435A (zh) * | 2010-11-23 | 2017-10-20 | Abbvie 公司 | 细胞凋亡诱导剂的盐和晶形 |
-
2014
- 2014-03-12 HU HUE14715501A patent/HUE039046T2/hu unknown
- 2014-03-12 EP EP19183264.1A patent/EP3569588A1/en not_active Withdrawn
- 2014-03-12 SI SI201430826T patent/SI2970263T1/sl unknown
- 2014-03-12 CA CA3183040A patent/CA3183040A1/en active Pending
- 2014-03-12 CA CA2903797A patent/CA2903797C/en active Active
- 2014-03-12 UY UY0001035394A patent/UY35394A/es active IP Right Grant
- 2014-03-12 UY UY0001039847A patent/UY39847A/es not_active Application Discontinuation
- 2014-03-12 ES ES14715501.4T patent/ES2683378T3/es active Active
- 2014-03-12 PE PE2015001892A patent/PE20151809A1/es unknown
- 2014-03-12 AU AU2014248742A patent/AU2014248742B2/en active Active
- 2014-03-12 JP JP2016501441A patent/JP6357220B2/ja active Active
- 2014-03-12 TW TW103108953A patent/TWI631121B/zh not_active IP Right Cessation
- 2014-03-12 EP EP21194409.5A patent/EP3954687A1/en active Pending
- 2014-03-12 KR KR1020157029117A patent/KR102230339B1/ko active IP Right Grant
- 2014-03-12 MY MYPI2019006129A patent/MY192466A/en unknown
- 2014-03-12 PL PL14715501T patent/PL2970263T3/pl unknown
- 2014-03-12 DK DK14715501.4T patent/DK2970263T3/en active
- 2014-03-12 UY UY0001039848A patent/UY39848A/es not_active Application Discontinuation
- 2014-03-12 TW TW107109344A patent/TWI735759B/zh not_active IP Right Cessation
- 2014-03-12 EP EP17191299.1A patent/EP3293185A1/en not_active Withdrawn
- 2014-03-12 CN CN201480025215.7A patent/CN105164128B/zh active Active
- 2014-03-12 SG SG11201507360XA patent/SG11201507360XA/en unknown
- 2014-03-12 CN CN201711105971.2A patent/CN107721851B/zh active Active
- 2014-03-12 RU RU2015143637A patent/RU2660424C2/ru active
- 2014-03-12 MX MX2015012000A patent/MX365343B/es active IP Right Grant
- 2014-03-12 BR BR112015021540-8A patent/BR112015021540B1/pt active IP Right Grant
- 2014-03-12 CN CN202010877947.6A patent/CN111960944A/zh active Pending
- 2014-03-12 EP EP14715501.4A patent/EP2970263B1/en active Active
- 2014-03-12 CA CA3090936A patent/CA3090936C/en active Active
- 2014-03-12 BR BR122021025053-7A patent/BR122021025053B1/pt active IP Right Grant
- 2014-03-12 BR BR122021025062-6A patent/BR122021025062B1/pt active IP Right Grant
- 2014-03-12 LT LTEP14715501.4T patent/LT2970263T/lt unknown
- 2014-03-12 PE PE2019001821A patent/PE20191685A1/es unknown
- 2014-03-12 EP EP22154798.7A patent/EP4019491A1/en active Pending
- 2014-03-12 PT PT14715501T patent/PT2970263T/pt unknown
- 2014-03-12 SG SG10201701680YA patent/SG10201701680YA/en unknown
- 2014-03-12 WO PCT/US2014/024224 patent/WO2014165044A1/en active Application Filing
- 2014-03-12 RS RS20180939A patent/RS57569B1/sr unknown
- 2014-12-03 UA UAA201509919A patent/UA118667C2/uk unknown
-
2015
- 2015-08-24 IL IL240779A patent/IL240779B/en active IP Right Grant
- 2015-09-04 PH PH12015501960A patent/PH12015501960B1/en unknown
- 2015-09-09 CL CL2015002548A patent/CL2015002548A1/es unknown
- 2015-09-16 CR CR20150495A patent/CR20150495A/es unknown
-
2016
- 2016-04-22 HK HK18110753.6A patent/HK1251231A1/zh unknown
- 2016-04-22 HK HK16104667.6A patent/HK1216644A1/zh unknown
-
2018
- 2018-01-23 IL IL257109A patent/IL257109B/en active IP Right Grant
- 2018-04-13 JP JP2018077547A patent/JP6578037B2/ja active Active
- 2018-05-21 PH PH12018501094A patent/PH12018501094A1/en unknown
- 2018-06-05 AU AU2018203977A patent/AU2018203977B2/en active Active
- 2018-08-09 CY CY20181100834T patent/CY1120576T1/el unknown
- 2018-08-09 HR HRP20181273TT patent/HRP20181273T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6578037B2 (ja) | アポトーシス誘導剤の調製のための方法 | |
US9199992B2 (en) | Processes for the preparation of an apoptosis-inducing agent | |
JP7365349B2 (ja) | 一酸化窒素を供与するプロスタグランジン類似体の製造方法 | |
KR20130047685A (ko) | 2(사이클로헥실메틸)n{2[(2s)1메틸피롤리딘2일]에틸}1,2,3,4테트라하이드로이소퀴놀린7설폰아마이드의 제조 방법 | |
US9238652B2 (en) | Processes for the preparation of an apoptosis-inducing agent | |
NZ711315B2 (en) | Processes for the preparation of an apoptosis-inducing agent | |
JP2021075535A (ja) | ピリミジン誘導体およびそれらの中間体を調製する化学的方法 | |
JP2019196359A (ja) | ピリミジン誘導体およびそれらの中間体を調製する化学的方法 | |
JP2016503068A (ja) | パピローマウイルスの治療で用いることができるヒドラジンの合成方法 | |
JP2013006804A (ja) | ベンゾフェノン誘導体の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180507 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180507 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190403 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190423 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190717 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190730 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190823 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6578037 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |